Abcon Therapeutics

Abcon Therapeutics is a preclinical-stage biotechnology company focused on the development of next-generation antibody-based therapeutics, specifically bispecific antibodies and antibody-drug conjugates (ADCs). The company leverages a proprietary discovery platform to identify and optimize novel antibody candidates with enhanced specificity and potency for treating various forms of cancer. Founded by experts in molecular biology and nanotechnology, Abcon aims to address limitations in current targeted therapies by improving the therapeutic window and overcoming resistance mechanisms in solid tumors. The company is backed by leading venture capital firms, including Arch Venture Partners, and maintains strong ties to academic research institutions like Northwestern University. Abcon's approach integrates high-throughput screening with advanced engineering to accelerate the transition from discovery to clinical development. The leadership team includes prominent figures in the fields of translational medicine and biotechnology entrepreneurship.